FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065035511> ?p ?o ?g. }

• W2065035511 endingPage "292" @default.
• W2065035511 startingPage "286" @default.
• W2065035511 abstract "Gene modification of tumor cells with the cDNA for interferon γ (IFNγ) has been shown to increase the immunogenicity of some tumor cells. In order to explore further the possible therapeutic relevance of these previous findings, two clones of the nonimmunogenic MCA-102 fibrosarcoma of C57BL/6 origin were retrovirally transduced with the cDNA encoding murine IFNγ: 102.4JK (4JK), a clone with relatively high major histocompatibility complex (MHC) class I expression, and 102.24JK (24JK), a clone with low expression of surface MHC class I molecules. Retroviral transduction of tumor cells with the cDNA encoding for IFNγ resulted in a substantial up-regulation of MHC class I surface expression in the 24JK clone but little change of class I in the 4JK clone. In an attempt to generate antitumor lymphocytes, these gene-modified cells were inoculated into mouse footpads and draining lymph nodes (DLN) were removed, dispersed, and cultured in vitro for 10 days with irradiated tumor cells and interleukin-2. DLN from mice bearing either unmodified tumor or tumor transduced with cDNA encoding neomycin resistance (Neo R) or IFNγ, were used to treat recipients harboring 3-day pulmonary metastases induced by the parental, unmodified tumor. Treatment with DLN cells obtained following the injection of 24JK tumor cells modified with the gene for IFNγ significantly reduced the number of pulmonary metastases in four separate experiments, compared to groups treated by DLN cells generated from inoculation of either the unmodified, parental 24JK clone or the same clone transduced with theNeo R gene only. In contrast, DLN cells induced either by IFNγ-transduced 4JK (high expression of MHC class I) or an unmodified 4JK tumor (moderate expression of MHC class I) had significant but equal therapeutic efficacy. Although the in vitro growth rate of tumor cell lines was unaffected by the insertion of the mouse IFNγ cDNA, their in vivo (s.c.) growth rates were significantly slower than those of the nontransduced tumors. Thus, after retroviral transduction of the murine IFNγ cDNA into a nonimmunogenic tumor with a very low level of surface expression of MHC class I, modified tumor cells could elicit therapeutic T cells from DLN capable of successfully treating established pulmonary metastases upon adoptive transfer. This strategy significantly confirms previous observations on the potential therapeutic effects of gene modification of tumor cells with IFNγ and extends the realm of therapeutic possibilities to include the use of DLN cells for the development of T-cell based immunotherapies against nonimmunogenic human tumors." @default.
• W2065035511 created "2016-06-24" @default.
• W2065035511 creator A5004554374 @default.
• W2065035511 creator A5005611842 @default.
• W2065035511 creator A5039197753 @default.
• W2065035511 creator A5040600420 @default.
• W2065035511 creator A5061987607 @default.
• W2065035511 creator A5072133376 @default.
• W2065035511 creator A5083623954 @default.
• W2065035511 date "1993-09-01" @default.
• W2065035511 modified "2023-09-24" @default.
• W2065035511 title "Retroviral transduction of interferon-? cDNA into a nonimmunogenic murinefibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor" @default.
• W2065035511 cites W1444462873 @default.
• W2065035511 cites W1483963831 @default.
• W2065035511 cites W1578438134 @default.
• W2065035511 cites W1593345533 @default.
• W2065035511 cites W1819529703 @default.
• W2065035511 cites W1898114229 @default.
• W2065035511 cites W1970392021 @default.
• W2065035511 cites W1973291904 @default.
• W2065035511 cites W1976548176 @default.
• W2065035511 cites W2006987944 @default.
• W2065035511 cites W2009228522 @default.
• W2065035511 cites W2010955189 @default.
• W2065035511 cites W2014113952 @default.
• W2065035511 cites W2029793114 @default.
• W2065035511 cites W2030005722 @default.
• W2065035511 cites W2033394004 @default.
• W2065035511 cites W2041282815 @default.
• W2065035511 cites W2053093244 @default.
• W2065035511 cites W2055034075 @default.
• W2065035511 cites W2056415484 @default.
• W2065035511 cites W2066656768 @default.
• W2065035511 cites W2068032204 @default.
• W2065035511 cites W2068379381 @default.
• W2065035511 cites W2068494547 @default.
• W2065035511 cites W2083988731 @default.
• W2065035511 cites W2122334788 @default.
• W2065035511 cites W2131406588 @default.
• W2065035511 cites W2160015737 @default.
• W2065035511 cites W2170889183 @default.
• W2065035511 cites W2173997865 @default.
• W2065035511 cites W2335365056 @default.
• W2065035511 cites W342703717 @default.
• W2065035511 doi "https://doi.org/10.1007/bf01518450" @default.
• W2065035511 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2248452" @default.
• W2065035511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8402732" @default.
• W2065035511 hasPublicationYear "1993" @default.
• W2065035511 type Work @default.
• W2065035511 sameAs 2065035511 @default.
• W2065035511 citedByCount "26" @default.
• W2065035511 countsByYear W20650355112012 @default.
• W2065035511 countsByYear W20650355112013 @default.
• W2065035511 countsByYear W20650355112015 @default.
• W2065035511 countsByYear W20650355112016 @default.
• W2065035511 countsByYear W20650355112017 @default.
• W2065035511 countsByYear W20650355112019 @default.
• W2065035511 countsByYear W20650355112022 @default.
• W2065035511 crossrefType "journal-article" @default.
• W2065035511 hasAuthorship W2065035511A5004554374 @default.
• W2065035511 hasAuthorship W2065035511A5005611842 @default.
• W2065035511 hasAuthorship W2065035511A5039197753 @default.
• W2065035511 hasAuthorship W2065035511A5040600420 @default.
• W2065035511 hasAuthorship W2065035511A5061987607 @default.
• W2065035511 hasAuthorship W2065035511A5072133376 @default.
• W2065035511 hasAuthorship W2065035511A5083623954 @default.
• W2065035511 hasBestOaLocation W20650355112 @default.
• W2065035511 hasConcept C104317684 @default.
• W2065035511 hasConcept C15152581 @default.
• W2065035511 hasConcept C153911025 @default.
• W2065035511 hasConcept C159047783 @default.
• W2065035511 hasConcept C170627219 @default.
• W2065035511 hasConcept C187882448 @default.
• W2065035511 hasConcept C203014093 @default.
• W2065035511 hasConcept C207936829 @default.
• W2065035511 hasConcept C2776178377 @default.
• W2065035511 hasConcept C502942594 @default.
• W2065035511 hasConcept C54355233 @default.
• W2065035511 hasConcept C55493867 @default.
• W2065035511 hasConcept C81089528 @default.
• W2065035511 hasConcept C86803240 @default.
• W2065035511 hasConcept C8891405 @default.
• W2065035511 hasConceptScore W2065035511C104317684 @default.
• W2065035511 hasConceptScore W2065035511C15152581 @default.
• W2065035511 hasConceptScore W2065035511C153911025 @default.
• W2065035511 hasConceptScore W2065035511C159047783 @default.
• W2065035511 hasConceptScore W2065035511C170627219 @default.
• W2065035511 hasConceptScore W2065035511C187882448 @default.
• W2065035511 hasConceptScore W2065035511C203014093 @default.
• W2065035511 hasConceptScore W2065035511C207936829 @default.
• W2065035511 hasConceptScore W2065035511C2776178377 @default.
• W2065035511 hasConceptScore W2065035511C502942594 @default.
• W2065035511 hasConceptScore W2065035511C54355233 @default.
• W2065035511 hasConceptScore W2065035511C55493867 @default.
• W2065035511 hasConceptScore W2065035511C81089528 @default.
• W2065035511 hasConceptScore W2065035511C86803240 @default.
• W2065035511 hasConceptScore W2065035511C8891405 @default.
• W2065035511 hasIssue "5" @default.

• next